Non-genetic factors play a more important role in lansoprazole metabolism than CYP2C19 pharmacogenetic profiles in European patients with burns.

Single nucleotide variants in the CYP2C19 gene, as well as some non-genetic factors, are associated with the effectiveness of most proton pump inhibitors used for stress ulcer prophylaxis and should be considered in personalized treatment. In this study, we aimed to determine the CYP2C19*2 and *17 haplogenotypes by qPCR and the concentration of lansoprazole and its metabolites using HPLC in 50 burn patients from the European population on their first-ever lansoprazole prophylaxis. While CYP2C19 pharmacogenetic profiling in patients with burns played no significant role in predicting their ability to metabolize lansoprazole, associations of non-genetic factors with lansoprazole metabolism, such as age, sex, BMI, smoking, or substance abuse, were detected. Our results suggest that when prescribing lansoprazole to prevent stress ulcers in burn patients from the European population, the effect of genetic predispositions might be lower than that of other factors. Generalizability to other populations with different genetic backgrounds is, however, limited, and further studies with larger groups of CYP2C19*2 carriers in an acute setting are needed.